A closer look at the function and efficicacy of niraparib as a maintenace treatment.
zejula
-
July 11, 2018
-
May 11, 2018
The European Medicines Agency has recently approved Niraparib (Zejula) for use in the European Union as a treatment for women struggling with a specific type of advanced ovarian cancer known as high-grade serous epithelial ovarian cancer, which includes cancers that affect the peritoneum and/or the fallopian tubes.